Pharmacogenetic Analysis of Korean Pediatric Patients With Acute Lymphoblastic Leukemia
Cure rate of pediatric ALL dramatically improved over 80%. Resistance to drug and
hematologic relapse are remaining problem in ALL treatment. One of the explanations of drug
resistance and toxicities is the pharmacogenetic effect. Germline polymorphisms in genes
that code for proteins involved in the pharmacokinetics and pharmacodynamics of antileukemic
agents are various, and inter-patient variability is the main factor for pharmacogenetic
difference. Since multiple chemotherapeutic agents are involved in treating ALL, many genes
related to the metabolic pathways of those drugs have an effect on the pharmacokinetics of
patients with ALL. In Korea, pharmacogenetic study including multiple genetic loci for
pediatric ALL has not been reported.In this study, the distribution of genetic polymorphisms
and genes related to antileukemic drugs were analyzed, and their relations to the outcome of
treatment and relapse rates were assessed.
Time Perspective: Retrospective
To find out distribution of genetic polymorphisms genes related to the pharmacodynamics of the ALL therapy
The distribution of each genetic polymorphism is descriped. The differences in genetic polymorphism between risk groups (high vs. standard) are analyzed using the chi-square test or Fisher's exact test.
up to 3 years from diagnosis
Hyo Seop Ahn, MD. PhD.
Seoul National University Hospital
Korea: Food and Drug Administration